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The occurrence of radiation-induced toxicity is a very 
complex process that is always modulated by the individual 
[2]; if two patients receive the “same dose distribution” they 
will likely have different reactions and possibly one will 
experience toxicity while the other not. The availability of 
individual information potentially characterizing the patient 
response, including the “omics” information, is highly 
valuable, especially in the “high-tech” era of image-
guided/adaptive IMRT in which organs are more efficiently 
spared: the better sparing reduces the incidence and severity 
of toxicities and, at the same time, enhances the impact of 
individual sensitivity factors. This point reinforces the need 
to create large data bases including individually assessed 
clinical, biological and genetic information, in addition to the 
individual dose distribution. As a consequence, the approach 
of quantitatively modelling dose-volume relationships is 
increasingly becoming “phenomenological” [3]: robust 
methods for (dosimetric and non-dosimetric) variable 
selection able to condense the information in “reliable”, 
friendly to use, predictive models is a major field of 
research: the adaptation of statistical methods for data-
mining and to avoid over-fitting is a pivotal point of the 
story.  
Although the potentials of large data bases and of data 
sharing platforms on toxicity modelling are clear [4], we 
should not forget that the creation of large data-bases is not 
the “aim” but is a (powerful) “tool”. The outcome of the 
process in terms of robustness and reliability of the models 
will not only depend on the “numbers” (a highly important 
component) but also (and maybe more importantly) on the 
“quality” of data. Differently from the “easy” score of the 
success of a therapy (survival, tumour control), toxicity is a 
much more complex issue that deserves specific attention 
and the careful collection of patient-reported and/or 
physician-reported information, often for years. Well 
assessed prospective observational studies focused on 
specific toxicities seem to be the best choice; secondary 
analyses of high-quality data coming from controlled trials 
are also very important although they may be limited in some 
cases by too homogenous protocols restricting the spread of 
the delivered dose distributions.  
At the end of the circle, the external validation of integrated 
dose-volume models is clearly a crucial component of the 
next year’s research [3]: testing the generalizability of dose-
volume models will be a major end-points. In addition, robust 
results from phenomenological models are expected to feed 
up mechanistic approaches in a sort of mutual synergy that 
can further corroborate our knowledge: these two 
components (mechanistic and phenomenological) will likely 
cooperate much more in the next future. Relevant 
developments are expected to impact the quantitative 
modelling of normal tissue effects also from the side of the 
dosimetry data. The robust, organ-planning-DVH approach to 
quantitatively describe the relationship between 
dose/volume and toxicities should be overcome/refined in 
many relevant situations by directly looking to the 3D dose 
distribution, integrating the spatial information lost when 
using “classical” surrogates like DVH/EUD. Relevant examples 
are: the direct measurement of dose-map dissimilarities 
between patients [5], the quantification of local (and organ) 
effects by imaging biomarkers [6], the interplay between the 
dose received by different organs, the impact of anatomy 
changes during therapy and their incorporation into normal 
tissue predictive models.  
Quantitative modelling of normal tissue effects is lively 
present in current century and seems to have a brilliant 
future in contributing to rapidly improve the way we treat 
our patients with the promise to continuously reduce 
toxicity.  
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Drawing on experience as a practicing GP with a special 
interest in communication skills and shared decision making, 
the work of The Health Foundation funded MAGIC (Making 
Good decisions in Collaboration) programme and most 
recently on a collaboration with a Danish Oncology Hospital, 
Dr Dave Tomson will explore recent developments in Shared 
Decision Making (SDM). Using experience and expertise from 
the delegates we will 
a) check out attitudes and beliefs about the need and 
rationale for putting SDM centre stage in patient interactions,  
b) look at a useful model of SDM both for personal clinical 
practice and for teaching other clinicians,  
c) explore some of the key skills needed and the key 
challenges in doing better SDM with a particular focus on 
oncology – the constant changing nature of the evidence 
base, individualised care in a guideline driven world, dealing 
with personal bias, unwarranted versus warranted variation 
in practice, the tyranny of time.  
d) share some ideas about possible solutions to these 
challenges and think about some of the steps needed to both 
develop personal practice and implement programmes of 
development within departments and across hospital systems 
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Although various effective anti-cancer treatments have 
become available over the last decades, therapy resistance 
remains the major cause of death of cancer patients. Striking 
examples are patients with tumors that are defective in DNA 
repair by homologous recombination (HR). Despite initial 
responses to cancer therapy, resistance of primary or 
disseminated tumors eventually emerges, which minimizes 
therapeutic options and greatly reduces survival. The 
molecular mechanisms underlying this therapy escape are 
often poorly understood.  
A clinically relevant mechanism for the defect in HR is a lack 
of function of BRCA1. This defect impairs error-free repair of 
DNA double-strand breaks (DSB) – a feature that can be 
exploited by the treatment with DSB-inducing agents. Using 
the K14cre,Brca1F/F,p53F/F (KB1P) genetically engineered 
mouse model for BRCA1-mutated breast cancer, we have 
shown the success of this strategy. Tumors are highly 
sensitive to DNA cross-linking agents, or to the inhibition of 
topoisomerase I/II and poly (ADP-ribose) polymerase (PARP) 
(reviewed by Rottenberg & Borst, 2012). Despite this 
sensitivity, tumors are not eradicated and eventually drug-
refractory tumors emerge. In several of the resistant tumors 
we found that the HR defect can be partially rescued by 
down-regulation or knock-out of additional repair factors, 
such as 53BP1 (Jaspers et al. 2013) or REV7 (Xu et al. 2015).  
Based on these observations we set out to investigate 
whether this type of HR restoration can also explain 
radiotherapy resistance. For this purpose, we treated mice 
carrying KB1P tumors with high-precision radiotherapy. We 
